For citations:
Petrov V.I., Ryazanova A.Yu., Tokareva N.S. Risk of secondary bacterial infections during treatment with anti-inflammatory genetically engineered biological drugs in COVID-19 patients. Pharmacy & Pharmacology. 2024;12(3):209-218. https://doi.org/10.19163/2307-9266-2024-12-3-209-218